Figure 5 from Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action
O’Connor JPB., Tessyman V., Little RA., Babur M., Forster D., Latif A., Cheung S., Lipowska-Bhalla G., Higgins GS., Asselin M-C., Parker GJM., Williams KJ.
<p>MRI elucidates differential drug mechanism of action for banoxantrone and atovaquone. Banoxantrone did not cause growth inhibition in (<b>A)</b> Calu6 xenografts or (<b>B</b>) U87 xenografts. Atovaquone did not cause growth inhibition in (<b>C)</b> Calu6 xenografts. <b>D</b> and <b>E,</b> Calu6 and U87 xenografts show reduction in volume of hypoxic tumor with banoxantrone by day 3. Similarly, (<b>F</b>) Calu6 xenografts show reduction in volume of hypoxic tumor with atovaquone by day 7. <b>G</b> and <b>H,</b> Calu6 and U87 xenografts show companion increases in volume of necrotic tumor, whereas (<b>I</b>) no change in volume of necrotic tumor is detected in Calu6 xenografts treated with atovaquone. <b>J</b> and <b>K,</b> No change in volume of normoxic tumor is detected in Calu6 or U87 xenografts treated with banoxantrone, whereas (<b>L</b>) Calu6 xenografts treated with atovaquone show increase in normoxic tumor. Changes described are all relative to baseline.</p>